795 related articles for article (PubMed ID: 23147456)
1. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
2. Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports.
Dubrall D; Schmid M; Stingl JC; Sachs B
PLoS One; 2020; 15(3):e0230632. PubMed ID: 32214375
[TBL] [Abstract][Full Text] [Related]
3. Angioedema related to Angiotensin inhibitors.
Knecht SE; Dunn SP; Macaulay TE
J Pharm Pract; 2014 Oct; 27(5):461-5. PubMed ID: 25124378
[TBL] [Abstract][Full Text] [Related]
4. Multivariable confounding adjustment in distributed data networks without sharing of patient-level data.
Toh S; Reichman ME; Houstoun M; Ding X; Fireman BH; Gravel E; Levenson M; Li L; Moyneur E; Shoaibi A; Zornberg G; Hennessy S
Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1171-7. PubMed ID: 23878013
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers.
Opelz G; Döhler B
Transplantation; 2014 Feb; 97(3):310-5. PubMed ID: 24492421
[TBL] [Abstract][Full Text] [Related]
6. Angioedema Among Hypertensive Patients Treated with Aliskiren or Other Antihypertensive Medications in the United States.
Schlienger RG; Korn JR; Wehler E; Lopez Leon S; Yeaw J
Am J Cardiovasc Drugs; 2017 Dec; 17(6):465-474. PubMed ID: 28779444
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors.
Makani H; Messerli FH; Romero J; Wever-Pinzon O; Korniyenko A; Berrios RS; Bangalore S
Am J Cardiol; 2012 Aug; 110(3):383-91. PubMed ID: 22521308
[TBL] [Abstract][Full Text] [Related]
8. The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase.
Alharbi FF; Kholod AAV; Souverein PC; Meyboom RH; de Groot MCH; de Boer A; Klungel OH
Fundam Clin Pharmacol; 2017 Dec; 31(6):676-684. PubMed ID: 28767167
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.
Kyrmizakis DE; Papadakis CE; Liolios AD; Karatzanis AD; Malandrakis S; Skoulakis CE; Bizakis JG; Velegrakis GA
Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1416-9. PubMed ID: 15611402
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
12. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
13. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive drug associated angioedema: effect modification by race/ethnicity.
Reichman ME; Wernecke M; Graham DJ; Liao J; Yap J; Chillarige Y; Southworth MR; Keeton S; Goulding MR; Mott K; Kelman JA
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1190-1196. PubMed ID: 28722207
[TBL] [Abstract][Full Text] [Related]
16. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
St Peter WL; Odum LE; Whaley-Connell AT
Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study.
Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
19. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer.
Mandilaras V; Bouganim N; Yin H; Asselah J; Azoulay L
Br J Cancer; 2017 Jan; 116(1):103-108. PubMed ID: 27846200
[TBL] [Abstract][Full Text] [Related]
20. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
